Home/Breye Therapeutics/Peter Adamson

PA

Peter Adamson

CSO

Breye Therapeutics

Therapeutic Areas

Ophthalmology Retinal Diseases

Breye Therapeutics Pipeline

Drug	Indication	Phase
Danegaptide	Diabetic Retinopathy	Phase 2
Oral P2X7 Receptor Antagonists	Diabetic Retinopathy / Age-related Macular Degeneration	Preclinical

Leadership Team at Breye Therapeutics

Ulrik Mouritzen

Kaare G Rasmussen

Financial Advisor

Benedikte el-Bandak Lind

Head of Clinical Operations

View full Breye Therapeutics profile